ACHFF - Arch Biopartners Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.7310
0.0000 (0.00%)
As of 10:26AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.7310
Open0.7400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.7310 - 0.7310
52 Week Range0.6500 - 1.0800
Volume6
Avg. Volume5,395
Market Cap43.757M
Beta (3Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)-0.0350
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Arch Biopartners Announces Issuance of U.S. Patent for Dipeptidase-1 Inhibitor Drug for Use in Acute Kidney Injury

    Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today the U.S. Patent and Trademark Office (USPTO) has issued to Arch U.S. Patent number 10,493,127 titled, “Dipeptidase-1 Binding Compositions and Methods of Treatment”. This is the first patent issued protecting the method of use for the dipeptidase-1 (DPEP-1) inhibitor, cilastatin, for ischemia reperfusion injury, where DPEP-1 mediated inflammation plays a major role. This patent complements the company’s lead drug candidate Metablok (LSALT peptide) and broadens Arch’s portfolio to target organ inflammation via the DPEP-1 pathway.

  • GlobeNewswire

    Arch Provides Interim Update on Phase I Trial for Metablok (LSALT Peptide)

    Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Phase I human trial of Metablok (LSALT peptide), the Company’s lead drug candidate for treating organ damage caused by inflammation, has met the primary endpoints of safety and tolerability in the trial’s three single ascending dose cohorts of healthy volunteers. This second part of the study, representing the expected dosing schedule for the Phase II trial, is expected to be completed by the end of November. Arch has been conducting the Phase I clinical trial for Metablok with 44 healthy volunteers in Melbourne, Australia.

  • GlobeNewswire

    Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate Metablok in the Prevention of Inflammation and Organ Damage

    Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Donna Senger, Dr. Stephen Robbins and Dr. Paul Kubes at the University of Calgary, and their collaborators, have published a paper in the journal Cell describing a novel mechanism action for inflammation mediated organ injury involving the recruitment of white blood cells (neutrophils) from the bloodstream into injured or infected organ tissues. DPEP1 is a novel therapeutic target for inflammatory diseases of these organs, including sepsis and cardiac surgery-associated acute kidney injury.

  • GlobeNewswire

    Arch Biopartners Announces Start of Phase I Human Trial for Metablok

    Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has initiated the Phase I human trial for Metablok (“LSALT peptide”), the Company’s lead drug candidate for treating acute kidney injury and other organ damage caused by inflammation. The Phase I trial, being conducted at the Alfred Hospital in Melbourne, Australia, is a double-blind, placebo-controlled, randomized, single and multiple ascending dose study to evaluate the safety and pharmacokinetic profile of Metablok in healthy participants. The Company also announced today that a shareholder of the Company exercised 50,000 warrants expiring in July, 2019 to buy 50,000 common shares of the Company for proceeds of $25,000.

  • GlobeNewswire

    Arch Biopartners Closes Convertible Note Financing

    Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has closed the non-brokered, unsecured convertible note (“Note”) financing it disclosed in a press release on May 17, 2019 for net proceeds of CAD $1,000,000 (the “Offering”). The Note matures on November 22, 2019 and will be convertible, at the option of the holder, into common shares in the capital of the Company (“Common Shares”) at a price per Common Share of $1.21, in the thirty-day period prior to the maturity of the Note. The Note bears simple interest of 5% per annum, which is payable in-kind by the Company with Common Shares to be issued at then market prices for the Common Shares and subject to TSX Venture Exchange (“TSXV”) approval.

  • GlobeNewswire

    Arch Biopartners Arranges Convertible Note Financing

    Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has arranged a non-brokered, unsecured convertible note (“Note”) financing for gross proceeds of CAD $1,000,000 (the “Offering”). The Note matures on November 22, 2019 and will be convertible, at the option of the holder, into common shares in the capital of the Company (“Common Shares”) at a price per Common Share of $1.21, in the thirty-day period prior to the maturity of the Note.

  • GlobeNewswire

    Arch Biopartners Receives Approval to Perform Phase I Clincial Trial for Metablok in Australia

    Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced that it has been granted approval by the Alfred Hospital Ethics Committee to perform a Phase I clinical trial for Metablok, the Company’s lead drug candidate for treating acute kidney injury and other organ damage caused by inflammation. A successful Phase I trial will be followed by a Phase II trial to investigate Metablok’s efficacy in the prevention of acute kidney injury in cardiac surgery patients.

  • GlobeNewswire

    Arch Biopartners Awarded NRC-IRAP Funding to Further Develop Metablok Drug Program

    Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced that the National Research Council – Industrial Research Assistance Program (“NRC-IRAP”) has approved funding totaling $200,000 for Arch scientists to further develop the Metablok (LSALT peptide) program. Metablok is the Company’s lead drug candidate for treating acute kidney injury and other organs damaged by inflammation. The NRC-IRAP funds will be used to advance the drug library that is now emerging at Arch as a result of the initial development of Metablok.

  • GlobeNewswire

    Arch Biopartners Forms New Subsidiary to Pursue a Phase I Trial in Australia for Metablok (LSALT Peptide)

    Arch Biopartners Inc., (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has formed a 100% owned subsidiary in Australia, named Arch Clinical Pty Ltd, to pursue an application to perform a phase I safety trial in Australia for Metablok, the Company’s lead drug candidate for treating acute kidney injury.